title: Phase I study of hyperfractionated accelerated radiation and simultaneous Carboplatin therapy for advanced head and neck carcinomas.
abstract: From 1990 to 1991 15 patients with advanced head and neck carcinomas underwent hyperfractionated accelerated radiotherapy (2 x 1.6 Gy/day, five days/week, total dose 64.0 to 67.2 Gy) and simultaneous intravenous application of Carboplatin (60 mg/m2, days 1 to 5 and 29 to 33) in a pilot study. Eleven patients had T4 and four had T3 tumours. At the end of treatment twelve patients had a complete tumour remission and in the others a partial tumour involution was seen. Although acute side-effects were more pronounced compared to conventional irradiation this treatment regimen is feasible and the initial complete remission rate of 80% is encouraging.
authors.affiliation: Department of Radiation Oncology, Heinrich-Heine-University, Düsseldorf.
authors.forename: T
authors.initials: T
authors.lastname: Schnabel
authors.forename: N
authors.initials: N
authors.lastname: Zamboglou
authors.forename: C
authors.initials: C
authors.lastname: Kolotas
authors.forename: W
authors.initials: W
authors.lastname: Jiménez
authors.forename: H
authors.initials: H
authors.lastname: Strehl
authors.forename: G
authors.initials: G
authors.lastname: Schmitt
mesh_terms: D000328:Adult; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D013997:Time Factors
chemical_list: D016190:Carboplatin